Our Pharmacy Operations
Check out our pharmacy industry overview study

• COVID-19 testing revenue of approximately $4.3 million

• Pharmacy dispensing revenue related to 340B earned $2.8 million on total billings of $19 million

• Gross margin increased to 26% in 2021, from 23% in 2020

• EBITDA increased to $167,000 in 2021 from $7,000 in 2020

• Cash balance of $1.4 million as of December 31,2021

Business Highlights for the Year Ended December 31, 2021

• Re-implemented upgraded pharmacy software system

• Expanded COVID-19 business into corporate-focused services and institutional clients

• Strengthened reputation in the 340B sector by adding eight new contracts

Q4 2021 Reflected a Positive Bounce Back in Business

• Increase of 10% in prescription revenue to $8.9 million in the fourth quarter of 2021, from $8.1 million in the third quarter of 2021

• Increase of 8% in prescriptions filled to 114,000 in the fourth quarter of 2021, from 106,000 in the third quarter of 2021

We enhance patient adherence to complex drug regimens, collect and report data, and ensure effective dispensing of medications to support the needs of patients, providers, and payors. Our patient and provider support services ensure appropriate drug initiation, facilitate patient compliance and persistence, and capture important information regarding safety and effectiveness of the medications that we dispense.


We have filled over 258,000 prescription during the six months ended June 30, 2020, compared to 187,000 prescriptions for the same period in 2019. Increases in prescriptions filled, physician referrals, and patients serviced stem from our value-added services and our performance as measured by Health Insurance Plans and PBMs. In 2019, our performance score was Five Stars with a relative ranking in the top 20% of all pharmacies in the U.S. Primary care physicians similarly are measured based on chronic care management, the results of which impact their annual revenue. This creates incentive for physicians to refer patients to pharmacies that have high performance scores. As a result of our pharmacy performance and value-added services we have helped retain customers and attract new ones and have resulted in performance incentives from PBMs of approximately $724,000 in 2019.

We provide contracted pharmacy services for 340B Covered Entities under the 340B Drug Discount Pricing Program. The drugs are owned by the 340B Covered Entity up until sale, so we do not incur out of pocket costs for this drug inventory. Under the terms of these agreements, we act as a pass through for reimbursements on prescription claims adjudicated on behalf of the 340B Covered Entities and receive a dispensing fee per prescription. These fees vary by the covered entity and the level of service we provide.

In 2015, we established a non-sterile compounding lab to support those patients looking for alternative primarily topical pain management treatments and customizable dosage forms to accommodate struggles with existing conditions. Our compounding department specializes in formularies such as non-narcotic topical pain creams, wound care creams, scar gels, hormone replacement therapies, female health, pediatrics, and sports medicine. We only use FDA approved and registered ingredients and each compounded prescription can be individually tailored for a result that fully meet the needs of the patient.  In addition to these medications, PharmCo prepares psoriasis creams, wellness vitamins, weight loss formulations and holistic capsules which are 100% Kosher and Halal certified. Compounded medications require strict compliance procedures, are highly labor intensive and as of 2020 are largely not covered by insurance. However, we continue to believe that compounded options must be available for our patients as they have proven effective in improving quality of life for patients with complex conditions and treatment regimens.


For our LTC customers, we provide purchasing, custom packaging and dispensing of both prescription and non-prescription pharmaceutical products. We utilize a best practice unit-of-dose packaging system as opposed to the traditional vials, using the same robotic packaging systems currently used by chain, mail order, and large-scale pharmacies. We also provide computerized maintenance of patient prescription histories, third party billing and consultant pharmacist services. Our consultant pharmacy services consist primarily of evaluation of monthly patient drug therapy, as well as monitoring the institution’s drug distribution system.


We also generate revenue from our work in MTM. MTM involves review and adjustment of prescribed drug therapies to improve patient health outcomes for patients with multiple prescriptions. This process includes several activities such as performing patient assessments, creating medication treatment plans, monitoring the effectiveness of and adherence to prescribed therapies and delivering documentation of these services to the patient’s physician to coordinate comprehensive care.

We currently deliver prescriptions to Florida’s diverse population and ship compounded medications to patients instates where we hold non-resident pharmacy licenses as well. We hold a community pharmacy permit in Florida and we hold non-resident pharmacy licenses that allow us to dispense to patients in the following states: Arizona, Colorado, Connecticut,  Georgia, Illinois, Massachusetts, Minnesota, Nevada, New Jersey, New York, Pennsylvania, Texas, and Utah.


We have isolated and prioritized key marketing methods which have yielded the lowest cost of customer acquisition and the most opportunity for growth.

Social media, website maintenance, and thought leadership are being optimized to promote brand awareness and recognition, which increases the likelihood of securing physician referrals and customer loyalty. For the years ended December 31, 2021 and 2020, we recognized overall revenue from operations of approximately $38.9 million in both years, which included revenue from COVID-19 testing of approximately $4.3 million and $0.6 million in 2021 and 2020, respectively. We have filled approximately 443,000 and 530,000 prescriptions during the twelve months ended December 31, 2021 and 2020, respectively, a 16% year over year decrease in the number of prescriptions filled. The decrease in prescriptions filled and pharmacy revenues are due to several factors as follows:

Total 2021 Revenues
COVID-19 Revenues
Filled Prescriptions in 2021